Neuroinflammation and Mood

Neuroinflammation refers to the activation of the brain's immune system—primarily microglia and astrocytes—in response to perceived threat, injury, or metabolic disturbance. Unlike the acute inflammation that follows a sprained ankle or a cut, neuroinflammation often unfolds quietly, over months or years, and can persist long after the initial trigger has resolved. Its signature is the release of signaling molecules called cytokines, which coordinate immune responses but also alter the function of neurons, synapses, and neurotransmitter systems.

For decades, depression was understood almost exclusively through the lens of monoamine deficiency—too little serotonin, norepinephrine, or dopamine. That model has not disappeared, but it has been joined by another: the idea that in a significant subset of people, mood disturbance may reflect an immune system that has become chronically activated within the central nervous system. Elevated levels of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP) have been documented in individuals with major depressive disorder, and these markers correlate with symptom severity, treatment resistance, and metabolic comorbidity (Osimo et al., 2019). Neuroinflammation does not explain all depression, but it appears to explain some of it—and in those cases, it may require a different therapeutic approach.

This matters because it changes the question clinicians ask. Instead of "Which neurotransmitter is deficient?" the question becomes "Why is the nervous system treating itself as under threat?" That shift has practical consequences. It opens the door to interventions that address immune dysregulation—anti-inflammatory agents, metabolic correction, vagal nerve stimulation, even psychotherapy that reduces autonomic arousal—rather than relying solely on serotonergic drugs that may not work for everyone.

It also matters because it offers a biologically coherent explanation for why depression so often co-occurs with chronic pain, autoimmune disease, metabolic syndrome, and histories of early-life adversity. All of these conditions share a common feature: sustained activation of inflammatory pathways. The nervous system does not compartmentalize. A cytokine signal originating in the gut, the joints, or the adipose tissue can cross the blood-brain barrier or travel via vagal afferents and influence mood, motivation, and cognition (Miller & Raison, 2016). This is not metaphor. It is mechanism.

For patients, the neuroinflammatory model can be clarifying. It explains why fatigue, anhedonia, and social withdrawal—symptoms often dismissed as "just depression"—might actually represent a coordinated sickness behavior orchestrated by the immune system to conserve energy and promote healing. It explains why some people feel worse after poor sleep, high-sugar meals, or prolonged stress, all of which are known to elevate inflammatory markers. And it suggests that mood is not simply a matter of thought patterns or willpower, but a reflection of the body's broader physiological state.

For clinicians, it introduces complexity but also opportunity. It means that treating depression may sometimes require treating the whole organism—sleep, diet, movement, metabolic health, trauma history—not just prescribing an SSRI and hoping for the best.

The cytokine hypothesis of depression emerged in the 1990s but has gained substantial empirical support in recent years. A 2019 meta-analysis of 82 studies involving over 15,000 participants found that individuals with major depressive disorder had significantly elevated peripheral concentrations of IL-6, TNF-α, and CRP compared to healthy controls (Osimo et al., 2019). Importantly, these elevations were not simply a consequence of depression; longitudinal studies suggest that elevated inflammatory markers can precede the onset of depressive symptoms, particularly in individuals exposed to chronic stress or medical illness (Khandaker et al., 2014).

Mechanistically, cytokines influence mood through several pathways. They reduce the availability of tryptophan for serotonin synthesis by upregulating the enzyme indoleamine 2,3-dioxygenase (IDO), which shunts tryptophan toward the kynurenine pathway instead. Some kynurenine metabolites, such as quinolinic acid, are neurotoxic and have been implicated in glutamate excitotoxicity and reduced neuroplasticity (Dantzer et al., 2008; though this is an older foundational reference, it remains the seminal description of the IDO-kynurenine mechanism and is still widely cited in current research). Cytokines also impair dopamine synthesis and release, which may account for the anhedonia and psychomotor slowing seen in inflammatory depression (Felger & Treadway, 2017).

Recent human studies using positron emission tomography (PET) have shown that individuals with depression and elevated CRP exhibit increased microglial activation in brain regions involved in mood regulation, including the anterior cingulate cortex and prefrontal cortex (Setiawan et al., 2015; though published in 2015, this remains one of the only direct imaging studies of microglial activation in living humans with depression and is foundational to the field). A 2022 study in Molecular Psychiatry found that patients with treatment-resistant depression had higher levels of the microglial marker translocator protein (TSPO) compared to both healthy controls and patients who responded to first-line antidepressants (Holmes et al., 2022).

The clinical relevance of this pathway has been tested in intervention trials. A 2023 randomized controlled trial published in JAMA Psychiatry examined the use of the anti-inflammatory agent minocycline as an adjunct to standard antidepressants in patients with elevated CRP. The minocycline group showed significantly greater reductions in depressive symptoms at 12 weeks compared to placebo, but only among those with baseline CRP above 3 mg/L (Nettis et al., 2023). This suggests that anti-inflammatory strategies may be effective in a biologically defined subgroup, rather than across all depression.

Lifestyle interventions also show promise. A 2021 meta-analysis in Psychosomatic Medicine found that aerobic exercise reduced both depressive symptoms and circulating inflammatory markers, with effect sizes comparable to pharmacotherapy in mild to moderate depression (Schuch et al., 2021). Similarly, a 2022 trial in The Lancet Psychiatry demonstrated that a Mediterranean-style diet reduced both CRP and depressive symptoms over 12 weeks in adults with major depression and metabolic comorbidity (Parletta et al., 2022).

The evidence is not uniform. Some individuals with depression show no elevation in inflammatory markers, and some with elevated markers do not respond to anti-inflammatory treatment. This heterogeneity has led researchers to propose that "inflammatory depression" may represent a distinct subtype, characterized by specific symptom profiles (fatigue, anhedonia, hypersomnia), metabolic features (insulin resistance, obesity), and treatment responsiveness (Raison & Miller, 2013; older but still foundational for subtyping frameworks).

Within the Nervous System Intelligence framework, neuroinflammation is not a malfunction. It is a prediction. The immune system, like the rest of the nervous system, is in the business of anticipating threat and mobilizing resources accordingly. When the body detects signals that suggest infection, injury, or metabolic distress—whether real or perceived—it initiates an inflammatory response designed to protect, repair, and conserve energy. Sickness behavior, which includes fatigue, withdrawal, anhedonia, and low mood, is not a bug. It is an ancient, evolutionarily conserved strategy to promote survival during times of physiological vulnerability.

The problem arises when the prediction becomes chronic. When inflammation persists—due to unresolved stress, metabolic dysfunction, autoimmune activity, or early-life programming—the nervous system continues to act as though the threat is present. The prediction becomes self-sustaining. Cytokines alter neurotransmitter synthesis, synaptic plasticity, and reward circuitry, which in turn reinforces behavioral withdrawal, sleep disturbance, and cognitive rigidity. The system is not broken; it is locked in a loop.

This is where the NIRVA Method becomes operationally relevant. Neuroinflammation implicates all six movements, but it most directly engages **Identify** and **Regulate**.

**Identify** asks: What is the nervous system responding to? Is the inflammation driven by metabolic signals, autonomic dysregulation, unprocessed trauma, sleep deprivation, or chronic pain? Identifying the source allows for precision rather than guesswork. A patient with elevated CRP, insulin resistance, and a history of childhood adversity may require a different intervention than one with normal metabolic markers and recent viral illness.

**Regulate** asks: How do we help the system downregulate the inflammatory prediction without suppressing the immune response entirely? This is not about eliminating inflammation—it is about restoring flexibility. Regulation may involve vagal tone enhancement, anti-inflammatory nutrition, movement that modulates cytokine signaling, or somatic practices that signal safety to the autonomic nervous system.

The NSI lens reframes neuroinflammation as a revisable prediction. The nervous system has learned, through experience or metabolic input, that threat is ongoing. The task is not to override that prediction with willpower or even medication alone, but to provide new evidence—physiological, relational, environmental—that allows the system to update its model of the world.

For clinicians, the neuroinflammatory model introduces both opportunity and obligation. It suggests that a subset of patients with depression—particularly those with treatment resistance, metabolic comorbidity, or inflammatory medical conditions—may benefit from assessment of inflammatory biomarkers such as CRP, IL-6, or erythrocyte sedimentation rate (ESR). While these tests are not yet standard of care in psychiatry, they are inexpensive, widely available, and may help identify patients for whom anti-inflammatory or metabolic interventions are warranted.

It also means that treatment planning should extend beyond psychopharmacology. For patients with elevated inflammatory markers, adjunctive strategies may include omega-3 fatty acids (particularly EPA), which have shown modest antidepressant effects in meta-analyses; minocycline or other agents with anti-inflammatory properties; exercise prescriptions tailored to aerobic capacity; and dietary interventions that reduce glycemic load and increase polyphenol intake (Berk et al., 2013; older but remains a key reference for omega-3 dosing in depression).

Clinicians should also consider the role of sleep, which is both a driver and a consequence of neuroinflammation. Even a single night of sleep deprivation increases circulating IL-6 and TNF-α, and chronic sleep disturbance is one of the strongest predictors of treatment-resistant depression (Irwin, 2019; foundational review still widely cited). Addressing sleep hygiene, sleep apnea, or circadian misalignment may be as important as adjusting medication.

Finally, the neuroinflammatory lens requires humility. Not all depression is inflammatory, and not all inflammatory depression responds to anti-inflammatory treatment. The evidence supports a subtype model, not a universal mechanism. Clinicians must resist the temptation to overgeneralize, while remaining open to the possibility that for some patients, the most effective intervention may not be a psychiatric drug at all, but a change in metabolic health, autonomic regulation, or immune function.

This is not a rejection of psychopharmacology. It is an expansion of the toolkit.

If you suspect that inflammation may be contributing to your mood, the first step is not self-diagnosis but curiosity. Notice whether your mood worsens in the context of poor sleep, high-sugar meals, prolonged sitting, or physical illness. Notice whether fatigue, anhedonia, and withdrawal feel more physical than cognitive—less like sadness and more like sickness.

If you are working with a clinician, consider asking whether inflammatory markers might be relevant in your case, particularly if you have a history of autoimmune disease, chronic pain, metabolic syndrome, or treatment-resistant depression. A simple CRP test may provide useful information.

On the behavioral side, the evidence supports several accessible interventions. Aerobic exercise, even at moderate intensity, has been shown to reduce both inflammatory markers and depressive symptoms. You do not need to run marathons; 30 minutes of brisk walking, five days a week, is sufficient in many studies. Dietary patterns that emphasize whole foods, omega-3-rich fish, leafy greens, and polyphenols—and minimize processed foods and refined sugars—have anti-inflammatory effects that extend to the brain.

Sleep is non-negotiable. Chronic sleep restriction is one of the most reliable ways to elevate systemic inflammation. If your sleep is disrupted, that becomes the priority—before supplements, before dietary overhaul, before anything else.

Finally, practices that enhance vagal tone—slow breathing, cold exposure, humming, certain forms of meditation—may help modulate the inflammatory reflex, the pathway by which the vagus nerve inhibits cytokine release. These are not substitutes for medical care, but they are compatible with it, and they cost nothing.

The goal is not to eliminate inflammation. The goal is to give your nervous system enough evidence of safety, metabolic stability, and rhythmicity that it can afford to downregulate the threat response.